Illumina Inc (NASDAQ:ILMN)

358.16
Delayed Data
As of Sep 21
 +1.84 / +0.52%
Today’s Change
196.00
Today|||52-Week Range
360.63
+63.93%
Year-to-Date
Is First Trust Multi Cap Growth AlphaDEX Fund (FAD) a Hot ETF Right Now?
Sep 21 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
Sep 14 / Zacks.com - Paid Partner Content
Major Stock Indexes Approaching Record Highs: 5 Top Picks
Sep 20 / Zacks.com - Paid Partner Content
DENTSPLY Launches Azento, Improves Digital Implant Workflow
Sep 14 / Zacks.com - Paid Partner Content
Cytori's Chemotherapy Candidate Gets Orphan Drug Status
Sep 18 / Zacks.com - Paid Partner Content
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
Sep 13 / Zacks.com - Paid Partner Content
5 Stocks Beating the Market
Sep 16 / GuruFocus News - Paid Partner Content
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
Sep 13 / Zacks.com - Paid Partner Content
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
Sep 14 / Zacks.com - Paid Partner Content
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
Sep 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close356.32
Today’s open358.10
Day’s range356.50 - 360.63
Volume1,171,341
Average volume (3 months)850,512
Market cap$52.4B
Data as of 4:00pm ET, 09/21/2018

Growth & Valuation

Earnings growth (last year)+59.56%
Earnings growth (this year)+35.24%
Earnings growth (next 5 years)+18.85%
Revenue growth (last year)+14.74%
P/E ratio81.6
Price/Sales11.75
Price/Book19.05

Competitors

 Today’s
change
Today’s
% change
BIIBBiogen+4.17+1.22%
TLRYTilray Inc-53.35-30.25%
NBIXNeurocrine Bioscienc...-0.61-0.51%
NKTRNektar Therapeutics+0.56+0.96%
Data as of 4:00pm ET, 09/21/2018

Financials

Next reporting dateOctober 22, 2018
EPS forecast (this quarter)$1.25
Annual revenue (last year)$2.8B
Annual profit (last year)$725.0M
Net profit margin26.34%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Francis A. deSouza
Executive Vice President-Products &
Operations
Ostadan Omead
Corporate headquarters
San Diego, California

Forecasts